In Vitro and in vivo activity of ARRY-380: A potent, small molecule inhibitor of ErbB2.

被引：0

作者：

Pheneger, Tracy ^{[1
]}

Bouhana, Karyn ^{[1
]}

Anderson, Deborah ^{[1
]}

Garrus, Jennifer ^{[1
]}

Ahrendt, Kateri ^{[1
]}

Allen, Shelley ^{[1
]}

Von Carlowitz, Ira ^{[1
]}

Greschuk, Julie ^{[1
]}

Gross, Stefan ^{[1
]}

Hoffman, Keith ^{[1
]}

Lemieux, Christine ^{[1
]}

Lyssikatos, Joe ^{[1
]}

Callejo, Michele ^{[1
]}

Tarlton, Gene ^{[1
]}

Wallace, Eli ^{[1
]}

Winski, Shannon ^{[1
]}

Woessner, Rich ^{[1
]}

Zhao, Qian ^{[1
]}

Marmsater, Fred ^{[1
]}

Lee, Patrice ^{[1
]}

机构：

[1] Array BioPharma, Boulder, CO USA

来源：

CANCER RESEARCH | 2009年 / 69卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1795

引用

页数：2

共 50 条

[1] In Vivo Activity of ARRY-380, a Potent, Small Molecule Inhibitor of ErbB2 in Combination with Trastuzumab, Docetaxel or Bevacizumab
Lee, P. A.
Anderson, D.
Bouhana, K.
Garrus, J.
Napier, C.
Avrustkaya, A.
White, A.
Pheneger, T.
Winkler, J.
CANCER RESEARCH, 2009, 69 (24) : 800S - 800S
[2] ARRY-380, a potent, small molecule inhibitor of ErbB2, increases survival in intracranial ErbB2+xenograft models in mice
Dinkel, Victoria
Anderson, Deborah
Winski, Shannon
Winkler, James
Koch, Kevin
Lee, Patrice A.
CANCER RESEARCH, 2012, 72
[3] In vivo activity of ARRY-380: A potent, small molecule inhibitor of ErbB-2 in combination with trastuzumab or docetaxel in a BT-474 human breast carcinoma xenograft model.
Lee, Patrice
Napier, Cheryl
Garrus, Jennifer
Avrustkaya, Anna
White, Angela
Winkler, Jim
CANCER RESEARCH, 2009, 69
[4] In vivo activity of ARRY-334543, a potent, small molecule inhibitor of EGFR, ErbB-2 and ErbB-4.
Pheneger, T. M.
Miknis, G.
Hans, J.
Topalov, G.
Tarlton, G.
Buckmelter, A.
Ren, L.
Tullis, J.
Lyssikatos, J.
Zhao, Q.
Hoffman, K.
Perrier, M.
Gross, S.
von Carlowitz, I
Lemieux, C.
Wallace, E.
Anderson, D.
Woessner, R.
Winski, S.
Lee, P. A.
BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S208 - S208
[5] In vivo activity of ARRY-334543, a potent, small molecule inhibitor of EGFR/ErbB2 in combination with trastuzumab or docetaxel
Anderson, Deborah
Napier, Cheryl
Avrustkaya, Anna
White, Angela
Pheneger, Tracy
Winkler, Jim
Lee, Patrice
CANCER RESEARCH, 2009, 69
[6] In vivo activity of ARRY-543, a potent, small molecule inhibitor of EGFR/ErbB-2 in combination with trastuzumab or docetaxel.
Lee, P. A.
Anderson, D.
Avrutskaya, A.
White, A.
Pheneger, T.
Winkler, J. D.
CANCER RESEARCH, 2009, 69 (02) : 200S - 200S
[7] In vivo anti-tumor activity of ARRY-334543, a small molecule inhibitor of EGFR and ErbB-2.
Pheneger, TM
Woessner, R
Lyssikatos, J
Miknis, G
Anderson, D
Winski, S
Lee, PA
CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9026S - 9026S
[8] ARRY-380, an oral HER2 inhibitor: Final phase 1 results and conclusions
Borges, Virginia F.
Chia, Steven K. L.
D'Aloisio, Susan
Fernetich, Gina
Sajan, Bessie
McSpadden, Tessa
Chavira, Renae
Barrett, Emma
Guthrie, Kari
Garrus, Jennifer
Baetz, Tara
Moulder, Stacy
MOLECULAR CANCER RESEARCH, 2013, 11
[9] ARRY-520, a KSP inhibitor with potent in vitro and in vivo efficacy and pharmacodynamic activity in models of multiple myeloma
Woessner, R.
Tunquist, B.
Chlipala, E.
Humphries, M.
Trawick, D.
Cox, A.
Lee, P.
Winkler, J.
Walker, D.
EJC SUPPLEMENTS, 2008, 6 (12): : 140 - 141
[10] A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity
Gowan, SM
Harrison, JR
Patterson, L
Valenti, M
Read, MA
Neidle, S
Kelland, LR
MOLECULAR PHARMACOLOGY, 2002, 61 (05) : 1154 - 1162

← 1 2 3 4 5 →